Yuyu Pharma, Inc.

A000220

KR7000220004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-26 EDT			5-day change	1st Jan Change
4,860 ^KRW	-0.31%		-2.80%	-7.95%

05-16	Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-20	Yuyu Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

August 03, 2021 at 04:00 am

Yuyu Pharma and Novartis Korea announced that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lamisil® for the treatment of athlete's foot; Lescol® XL for the treatment of dyslipidemia; and the Tegretol® for the treatment of epilepsy. This agreement will be in effect beginning August 1st, 2021.

Latest news about Yuyu Pharma, Inc.

Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Yuyu Pharma, Inc. announced that it has received KRW 24.5 billion in funding from a group of investors	23-05-21	CI
Yuyu Pharma, Inc. announced that it expects to receive KRW 24.5 billion in funding from a group of investors	23-05-17	CI
Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Yuyu Pharma Unveils the Results of Its Mechanism of Action and Head-To- Head Studies for Its Dry Eye Treatment Peptide	23-04-27	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Tranche Update on Yuyu Pharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	22-10-24	CI
Tranche Update on Yuyu Pharma, Inc.'s Equity Buyback Plan announced on September 19, 2022.	22-10-24	CI
Yuyu Pharma, Inc.'s Equity Buyback announced on September 19, 2022, has closed with 304,878 shares, representing 1.83% for KRW 1,785.24 million.	22-10-19	CI
Yuyu Pharma, Inc. announces an Equity Buyback for 304,878 shares.	22-09-18	CI
Yuyu Pharma, Inc. authorizes a Buyback Plan.	22-09-18	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Yuyu Pharma Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Disease	22-07-20	CI
Yuyu Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®	21-08-03	CI
Yuyu Pharma, Inc. announced that it has received KRW 30 billion in funding from a group of investors	21-06-14	CI
Yuyu Pharma, Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors	21-06-10	CI
Yuyu Pharma, Inc. Announces Management Changes	21-05-28	CI
Yuyu Pharma Announces the Introduction of its Global Anti-Corruption Management System	20-10-28	CI
Yuyu Pharma, Inc. announced that it has received KRW 10 billion in funding	20-04-23	CI
Yuyu Pharma, Inc. announced that it expects to receive KRW 10 billion in funding	20-04-21	CI

Chart Yuyu Pharma, Inc.

Duration

Period

More charts

Company Profile

Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
YUYU PHARMA, INC.	-7.95%	57.8M
MERCK KGAA	+16.17%	79.03B
KYOWA KIRIN CO. LTD.	+8.65%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-16.43%	4.83B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+48.34%	4.65B
YUHAN CORPORATION	+2.91%	3.89B
INDIVIOR PLC	+14.51%	2.34B
BETTA PHARMACEUTICALS CO., LTD.	-26.94%	2.18B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+16.55%	2.11B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.25%	2B

Specialty & Advanced Pharmaceuticals

Yuyu Pharma, Inc.

Equities

A000220

KR7000220004

Pharmaceuticals

Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®

Latest news about Yuyu Pharma, Inc.

Chart Yuyu Pharma, Inc.

Company Profile

Income Statement Evolution

Chiffre d''affaires - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals